
Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Watch Dr. Jamile M. Shammo, from Northwestern University Feinberg School of Medicine, discuss current treatment options in polycythemia vera during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron Gerds and Dr. Douglas Tremblay answer questions about essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Douglas A. Tremblay, from Mount Sinai, discuss treatment for essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron T. Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss essential thrombocythemia risk during the CURE Educated Patient MPN Summit.

Watch Dr. Francesco Maura, Dr. Marcella Kaddoura and Mary DeRome answer questions about the future of myeloma during the CURE® Educated Patient® Multiple Myeloma Summit.

Patients with breast cancer, regardless of their menopausal status, may face worse cognitive ability with chemotherapy and endocrine therapy, although this may return to its pretreatment level after 36 months.

Watch Dr. Marcella Kaddoura, from Miami Sylvester Comprehensive Cancer Center, discuss targeting myeloma with small molecules with precision medicine during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Francesco Maura, from Miami Sylvester Comprehensive Cancer Center, discuss how personalized prediction models can be used to identify the best treatments during the CURE® Educated Patient Multiple Myeloma Summit.

Watch Valarie Traynham, of the HealthTree Foundation, discuss the long-term journey of the disease and disparities still seen during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Dickran Kazandjian and Dr. Benjamin Diamond answer questions about therapeutic options during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Benjamin T. Diamond, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of sustained MRD negativity during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Dickran Kazandjian, from the Sylvester Comprehensive Cancer Center at the University of Miami, discuss available immunotherapy options during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. C. Ola Landgren and Dr. David Coffey answer questions about novel treatments and the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. David Coffey, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. C. Ola Landgren, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss novel treatments for newly diagnosed patients during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Leif Ellisen, Dr. Dejan Juric, Dr. Beverly Moy and Natasha Mmeje answer questions about unmet needs during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Beverly Moy, from Massachusetts General Hospital, discuss addressing breast cancer disparity during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Dejan Juric, from Massachusetts General Hospital, discuss therapeutic resistance during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Aditya Bardia, Dr. Arielle J. Medford and Dr. Neelima Vidula answer questions about HER2 and triple-negative disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Neelima Vidula, from Massachusetts General Hospital, discuss the management of triple-negative disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Arielle J. Medford, from Dana-Farber Cancer Institute, discuss the management of HER2-positive disease during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

Watch Dr. Aditya Bardia, Dr. Seth A. Wander and Dr. Laura M. Spring answer questions about HR-positive disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Laura M. Spring, from Massachusetts General Hospital in Boston, discuss treatment in third line and beyond for hormone receptor-positive breast cancer, during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

Watch Dr. Seth A. Wander, from Massachusetts General Hospital in Boston, discuss the first- and second-line treatment of hormone receptor-positive breast cancer, during the CURE® Educated Patient® Metastatic Breast Cancer Summit.